Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin add-on to metformin and sulphonylurea in type 2 diabetes
NCT01106625Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in Hemoglobin A1c From Baseline at 26 weeks. Started May 2010; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01106625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01106625.